Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch adds to Teva’s continued commitment to its complex ...

Generic Victoza is a GLP-1 receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with Type 2 diabetes as an adjunct to diet and exercise.

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Victoza ® (liraglutide) is a human glucagon-like peptide-1 (GLP-1) analog that was approved by the U.S. Food and Drug Administration on January 25, 2010, as an adjunct to diet and exercise to ...

Victoza (liraglutide) solution for injection is prescribed to help manage blood sugar and reduce major heart-related risks. Victoza is not safe to use while pregnant and may not be safe to use ...

Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced today the launch of an authorized generic of Victoza ® 1, in the United States.